Skip to main content

Table 4 Absolute risk difference of adverse events for vortioxetine compared to a serotonin norepinephrine reuptake inhibitor

From: The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis

 

1 mg

2.5 mg

5 mg

10 mg

15 mg

20 mg

Withdrawals due to adverse events

No trials

−6.2% (95% CI −10.7 to −1.8%)*; I2 = 0% 2 trials

−4.7% (95% CI −9.0 to −0.4%)*; I2 = 38% 4 trials

−4.4% (95% CI −9.7 to 0.9%); I2 = 0% 2 trials

2.3% (95% CI −1.7 to 6.3%); I2 = 0% 2 trials

4.4% (95% CI 0.1 to 8.7%)*; I2 = 0% 2 trials

Serious adverse events

 

−1.0% (95% CI −2.5 to 0.6%); I2 = 0% 2 trials

0.1%(95% CI −1.1 to 1.3%); I2 = 0% 4 trials

0.4% (95% CI −1.6 to 2.4%); I2 = 0% 2 trials

−0.3% (95% CI −3.6 to 3.1%); I2 = 74% 2 trials

−0.1% (95% CI −1.3 to 1.1%); I2 = 0% 2 trials

Nausea

 

−21.2% (95% CI −30.2 to −12.3%); I2 = 42% 2 trials

−12.2% (95% CI −17.4 to −7.0%); I2 = 0% 4 trials

−4.2% (95% CI −20.0 to 11.5%); I2 = 73% 2 trials

−2.8% (95% CI −10.3 to 4.7%); I2 = 73% 2 trials

−1.1% (95% CI −8.6 to 6.4%); I2 = 0% 2 trials

Vomiting

 

−2.8% (95% CI −5.5 to −0.1%)*; I2 = 0% 2 trials

−1.1% (95% CI −3.7 to 1.5%); I2 = 0% 3 trials

1.2% (95% CI −6.5 to 9.0%); I2 = 71% 2 trials

−3.2% (95% CI −8.8 to 2.3%) 1 trial

0.4% (95% CI −5.7 to 6.6%) 1 trials

Headache

 

−0.3% (95% CI −5.8 to 5.2%); I2 = 0% 2 trials

−1.8% (95% CI −5.8 to 2.2%); I2 = 0% 4 trials

−2.1% (95% CI −8.5 to 4.3%); I2 = 0% 2 trials

−0.6% (95% CI −6.0 to 4.9%); I2 = 0% 2 trials

−1.8% (95% CI −9.0 to 5.5%); I2 = 43% 2 trials

Diarrhea

 

−3.7% (95% CI −11.8 to 4.4%); I2 = 77% 2 trials

−1.8% (95% CI −5.0 to 1.4%); I2 = 26% 4 trials

1.5% (95% CI −2.4 to 5.3%); I2 = 0% 2 trials

−0.8% (95% CI −5.2 to 3.6%); I2 = 7% 2 trials

−1.6% (95% CI −7.6 to 4.4%); I2 = 46% 2 trials

Dizziness

 

−9.9% (95% CI −14.7 to −5.1%)*; I2 = 0% 2 trials

−7.0% (95% CI −12.5 to −1.5%)*; I2 = 62% 4 trials

−9.1% (95% CI −15.7 to −2.5%)*; I2 = 40% 2 trials

−5.7% (95% CI −10.3 to −1.0)*; I2 = 0% 2 trials

−4.2% (95% CI −9.0 to 0.6%); I2 = 0% 2 trials

Dry mouth

 

−9.5% (95% CI −22.7 to 3.8%); I2 = 86% 2 trials

−10.4% (95% CI −18.1 to 2.8%)*; I2 = 77% 4 trials

−5.2% (95% CI −9.8 to −0.5%)*; I2 = 5% 2 trials

−6.8% (95% CI −11.3 to −2.3%)*; I2 = 0% 2 trials

−3.4% (95% CI −8.3 to 1.5%); I2 = 0% 2 trials

Hyperhydrosis

 

−5.3% (95% CI −8.5 to −2.2%)*; I2 = 0% 2 trials

−6.0% (95% CI −9.5 to −2.6%)*; I2 = 35% 4 trials

−4.6% (95% CI −8.6 to −0.6%)*; I2 = 0% 2 trials

−4.5% (95% CI −7.5 to −1.4%)*; I2 = 0% 2 trials

−5.4% (95% CI −9.4 to −1.4%)*; I2 = 43% 2 trials

Nasopharyngitis

 

5.8% (95% CI 1.1 to 10.5%)* 1 trial

4.6% (95% CI 1.0 to 8.3%)*; I2 = 0% 2 trials

1.4% (95% CI −1.6 to 4.3%); I2 = 0% 2 trials

0.7% (95% CI −3.6 to 5.0%) 1 trial

2.5% (95% CI −2.2 to 7.2%) 1 trial

Insomnia

 

−3.3% (95% CI −7.1 to 0.5%); I2 = 0% 2 trials

−3.2% (95% CI −6.7 to 0.2%); I2 = 0% 3 trials

−6.4% (95% CI −10.5 to −2.3%)*; I2 = 0% 2 trials

−5.9% (95% CI −11.4 to −0.4%)* 1 trial

−0.9% (95% CI −7.3 to 5.5%) 1 trial

Fatigue

 

−5.3% (95% CI −8.3 to −2.3%)*; I2 = 0% 2 trials

−4.7% (95% CI −7.3 to −2.1%)*; I2 = 0% 4 trials

−3.3% (95% CI −6.9 to 0.3%); I2 = 0% 2 trials

−3.7% (95% CI −8.8 to 1.4%); I2 = 43% 2 trials

−3.6% (95% CI −7.6 to 0.3%); I2 = 11% 2 trials

  1. *P < 0.05.